Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 1999

View Archived Issues

Preliminary phase II results promising for Maxamine in HCV

LeukoSite announces important milestone, merger

Esteve sublicenses Surfaxin from Discovery for southern European territories, Latin America

Quarterly highlights at Isis underline commercial potential of antisense compounds

Human Genome Sciences reports results for third quarter

Japanese researchers demonstrate ability of HGF variant to halt renal tumor progression

NeXstar research leads to identification of new target for treating renal disease

New HOPE for high-risk patients with cardiovascular disease

Novel agents for renal diseases with benzimidazole structure

News from AHA: photoangioplasty with Antrin is safe and effective for PAD

Apoptosis inhibitors from JT useful for HIV infection and hepatitis

Modulators of MDR in development at Nikken Chemicals

Prognox effectively detects hypoxic tissue; kinetics differ in stunned and hibernating myocardium

Acetamide derivatives as chymase inhibitors patented by Nippon Kayaku

Taiho prepares novel agents for periodontitis

Etanidazole + radiosurgery for brain tumors fails to improve survival compared to radiosurgery alone

Heart Failure: Beyond Y2K -- a Prous Science webcast from the AHA

Clinical results for Enbrel in heart failure presented at AHA Scientific Sessions

Preclinical and interim clinical data presented for CN-706 at ASTRO

Combined data from three clinical trials of ibritumomab tiuxetan confirm safety in NHL

INTEGRITI study will evaluate fibrinogen antagonist/thrombolytic combination

Important new indication for Remicade approved by FDA

Insulin sensitizer improves cardiac function in diabetic mice

ELITE II fails to confirm results of ELITE; Merck drops HF indication for Cozaar

Canadian launch announced by Draxis for antispastic drug

Synergistic effects Na+/H+ exchange inhibitor and K(ATP) channel opener in MI

Synvisc under study for osteoarthritis of the hip

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...